Prevention of Deep-Venons Thrombosis after acute Myocardial Infarction. Comparison ot Effectiveness of ASA, Dipyridamole + ASA, and Phenprocoumon

In a controlled prospective trial of anti-aggregating drugs versus phenprocoumon, the incidence of deep-venous thrombosis (D. V. T.) was measured in 150 patients admitted with acute myocardial infarction in a coronary care unit. Patients moribund on admission, with a history of active peptic ulcer or hiatus hernia, a recent cerebrovascular accident, and those who used oral anticoagulants, aspirin, or anti-aggregating drugs regularly were excluded from participation. At admission the patients were randomly allocated to one of three treatment groups: 1.5 gram of acetylsalicylic acid (ASA) in 3 divided doses, a combination of 300 mg dipyridamole (in 4 divided doses) + 1.5 gram of ASA, or phenprocoumon. All patients were confined to bed for 12 days. 135 Patients completed the trial. The 3 groups were well matched statistically with regard to sex, age, weight, and coronary prognostic index. The ^l25I-fibrinogen test was used for detection of D. V. T.

The difference in frequency of D. V. T. between the ASA-group and the two other groups is highly significant (p < 0.01). The combination dipyridamole + ASA was as effective as phenprocoumon in the prevention of D. V. T. after acute myocardial infarction.

 

MissingLinkText

 

 

MissingLinkText